May. 12 at 6:40 PM
$PPBT
Asset breakdown for anyone actually doing homework:
• NT‑219 — A first‑in‑class IRS1/STAT3 inhibitor with a locked‑down 100mg dataset. That doesn’t happen unless the data matters.
• CM24 — Now eligible for streamlined approval thanks to the FDA’s updated single‑study rule. That’s a massive value unlock.
• Regulatory tailwind — Two assets now sitting in “approval‑ready” territory with the right confirmatory data.
• Advisory firepower — 12+ elite scientists backing a
$6M company. That mismatch alone tells a story.
• Institutional structure — Warrants and insider positions sitting far above current levels, meaning the upside math is institutional, not retail.
The pipeline value vs market cap gap is enormous.
